Vol. 8, Issue 6 (2019)

Author(s):
Dr. Vipul Gupta and Dr. Girish Khurana

Abstract:
The incretin system has become an crucial target in the treatment of type 2 diabetes in modern years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose-lowering effects. Glucagon-like peptide-1 (GLP-1)–based therapy betters glycaemic control through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of clinically relevant weight loss. Since Starling and Bayliss first proposed the existence of intestinal secretions that stimulate the pancreas, tremendous progress has been made in the area of incretins. Proper patient selection and education can assist in achieving positive treatment outcomes.